



09-14-01

GAU 1645

Docket No. 1151-4167

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED**

Applicant(s): Chang Yi Wang

Group Art Unit: 1645

SEP 17 2001

Serial No.: 09/865,294

Examiner: TBA

TECH CENTER 1600/2900

Filed: May 25, 2001

For: Synthetic Peptide Composition as Immunogens for Prevention of Alzheimer's Disease

EXPRESS MAIL CERTIFICATEExpress Mail Label No.: EL 912 003 304USDate of Deposit: September 13, 2001

I hereby certify that the following attached paper(s) and/or fee

1. Information Disclosure Statement;
2. Form PTO-1449;
3. 46 cited references; and
4. Return postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Susan Shen

(Typed or printed name of person mailing paper(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



St 18.01
Docket No. 1151-4167

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant(s): Chang Yi Wang

Group Art Unit: 1645

SEP 17 2001

Serial No.: 09/865,294

Examiner: TBA

TECH CENTER 1600/2900

Filed: May 25, 2001

For: Synthetic Peptide Composition as Immunogens for Prevention of Alzheimer's Disease

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to Rule 56, applicant hereby calls the attention of the Patent Office to the references listed on the attached Form PTO 1449. Copy(ies) of these references are attached were filed in related application U.S. Serial No(s) _____, filed _____, respectively.

- This document is being filed within three (3) months of the filing date of the application
- Please charge the \$180 fee to Deposit Account No. 13-4500, Order No. _____.
- This document is being concurrently filed with the above-identified application
- This document is being concurrently filed with an Request for Continued Examination (RCE)
- This document is being filed prior to a first Office Action
- This document is accompanied by a Search Report/Communication cited in a corresponding PCT or foreign counterpart application.
- The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 1151-4167. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: September 13, 2001

By:


Maria C.H. Lin
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



Applicant(s)
Chang Yi Wang

Docket No. 1151-4167

Serial No. : 09/865,294

Group Art Unit: 1645

Filed : May 25, 2001

Examiner: To Be Assigned

For : SYNTHETIC PEPTIDE COMPOSITION AS IMMUNOGENS FOR
PREVENTION OF ALZHEIMER'S DISEASE

CITED REFERENCES
INFORMATION DISCLOSURE STATEMENT (VOL. 1)

1. Anderton, Nature, 1987; 325:658-659
2. Araujo and Cotman, Brain Res., 1992; 569:141-145
3. Arispe et al., Proc. Natl. Acad. Sci. USA, 1993; 90:567-571
4. Babbitt et al., Nature, 1985; 317:359
5. Bard et al., Nature Medicine, 2000; 6:916-919
6. Barnes, Science, 1987; 235:846-847
7. Behl et al., Cell, 1994; 77:817-827
8. Busciglio et al., Neuron, 1995; 14:879-888
9. Cease et al., Proc. Natl. Acad. Sci. USA, 1987; 84:4249-4253
10. Chapman, Nature, 1992; 408:915-916
11. Citron et al., Nature, 1992; 360:672-674
12. Eldridge et al., Molec. Immunol., 1991; 28:287-294
13. Ferrari et al., J. Clin. Invest., 1991; 88:214-222
14. Fields et al., Synthetic Peptides: A User's Guide, Chapter 3, 1992:77-183
15. Frenkel et al., Proc. Natl. Acad. Sci. USA, 2000; 97:11455-11459
16. Frenkel et al., Vaccine, 2001; 19:2615-2619
17. Gaskin et al., JEM, 1987; 165:245
18. Glenner and Wong, Biochem Biophys Res Comm, 1984; 120:885-890
19. Glenner and Wong, Biochem Biophys Res Comm, 1984; 122:1131-1135
20. Goate et al., Nature, 1991; 349:704-706
21. Janus et al., Nature, 2000; 408:979-982
22. Johnson-Wood et al., Proc. Natl. Acad. Sci. USA, 1997; 94:1550-1555

23. Kang et al., Nature, 1987; 325:733-737
24. Klein et al., Trends in Neurosciences, 2001; 24:219-224
25. Masters et al., Proc. Natl. Acad. Sci. USA, 1985; 82:4245-4249
26. Meister et al., Vaccine, 1995; 13:581-591
27. Morgan et al., Nature, 2000; 408:982-985
28. Mullan et al., Nature Genetics, 1992; 1:345-347
29. O'Hagan et al., Vaccine, 1991; 9:768-771
30. Partidos et al., J. Gen. Virol., 1991; 72:1293
31. Schenk et al., Nature, 1999; 400:173-177
32. Selkoe, J. Biol. Chem., 1996; 271:18295-18298
33. Seubert et al., Nature, 1992; 359:325-327
34. Solomon et al., Proc. Natl. Acad. Sci. USA, 1996; 93:452-455
35. Solomon et al., Proc. Natl. Acad. Sci. USA, 1997; 94:4109-4112
36. Stagg et al., Immunology, 1993; 79:1-9
37. Terry et al., In Alzheimer Disease, 1999, 187-206
38. Thomas et al., Nature, 1996; 380:168-171
39. Wang et al., Science, 1991; 254:285-288
40. Yankner et al., Science, 1990; 250:279-282



RECEIVED

SEP 17 2001

TECH CENTER 1600/2900

Docket No. 1151-4167

Applicant(s) : Chang Yi Wang

Serial No. : 09/865,294

Group Art Unit: 1645

Filed : May 25, 2001

Examiner: To Be Assigned

For : SYNTHETIC PEPTIDE COMPOSITION AS IMMUNOGENS FOR
PREVENTION OF ALZHEIMER'S DISEASE

CITED REFERENCES

INFORMATION DISCLOSURE STATEMENT (VOL. 2)

41. WO 99/27944 Dale Schenk
42. EP 0 526 511 B1 Ellis L. Kline
43. U.S. 5,759,551 LADD et al.
44. U.S. 6,025,468 Chang Yi Wang
45. WO 95/11998 Chang Yi Wang
46. WO 99/66957 Chang Yi Wang